Dupixent® ( dupilumab ) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps ( CRSwNP ) - Regeneron Pharmaceuticals ( NASDAQ:REGN )
TARRYTOWN, N.Y. and PARIS, Sept. 13, 2024 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN and Sanofi today announced that the U.S.
| Ticker |
Sentiment |
Impact |
|
REGN
|
Neutral
|
5 %
|
|
META
|
Neutral
|
1 %
|
|
SNY
|
Neutral
|
15 %
|
